Midtown Manhattan skyline.
The inaugural CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference took place September 16-19, 2015, in New York, New York.
An EBV-infected cell (green/red)
among uninfected cells (blue)
Image by Benjamin
Type 2 Epstein-Barr virus (EBV) tumors, such as Hodgkin and non-Hodgkin lymphomas, are challenging to treat with virus-specific T (VST) cells, according to researchers. These lymphomas express a more restricted array of EBV antigens that are not particularly immunogenic. Nevertheless,... [Read Article]
Helen Heslop, MD
Photo courtesy of Baylor
College of Medicine
Researchers are creating virus-specific T cells (VST) to treat and prevent viral infections in patients who undergo hematopoietic stem cell transplant. Thus far, the group has modified T cells with 5 viral vectors—Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (ADV), BK virus (BKV), and human herpesvirus... [Read Article]
Researchers have developed a pharmaceutical-grade, third-generation, CD19-specific antibody that reduced minimal residual disease (MRD) in pediatric patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This chimerized, Fc-optimized antibody—4G7SDIE—was used on a compassionate-need basis in 14 patients with relapsed or refractory BCP-ALL. Nine of the patients had prior stem cell transplants.
... [Read Article]
Laurence Cooper, MD, PhD
Photo courtesy of MDACC
Researchers have used a nonviral approach to create chimeric antigen receptor (CAR) T cells and tested these cells in safety trials. Patients with advanced lymphoma or leukemia were infused with the nonvirally modified CD19-directed CAR T cells after autologous or allogeneic hematopoietic stem cell transplant (HSCT).... [Read Article]
Mette Hazenberg, MD, PhD
Investigators have found that B cells may play a role in stimulating graft-versus-leukemia (GvL) responses in patients with acute myeloid leukemia (AML) who have undergone allogeneic hematopoietic stem cell transplant (HSCT). The team created B cell lines from these patients, isolated AML-specific antibodies, and found that these antibodies can induce the... [Read Article]
Carl June, MD
Photo courtesy of the
University of Pennsylvania
The 5-year follow-up of the phase 1 trial of CTL019 in relapsed or refractory chronic lymphoblastic leukemia (CLL) is allowing investigators to define more clearly who will respond to chimeric antigen receptor (CAR) T cells directed against CD19. One thing investigators have determined... [Read Article]
Hannah Karlsson, PhD
For the first time, according to researchers, chimeric antigen receptor (CAR) T-cell therapy has been tested in a clinical trial in Sweden. Early results have shown the treatment can produce complete responses (CRs) in leukemia and lymphoma, although most patients ultimately progressed. Hannah Karlsson, PhD, of Uppsala University in Sweden, presented these... [Read Article]